10-Q Filing
Filing Information
| Form Type | 10-Q |
| Accession Number | 0000310158-22-000034 |
| Period End Date | 20220930 |
| Filing Date | 20221103 |
| Fiscal Year | 2022 |
| Fiscal Period | Q3 |
| XBRL Instance | mrk-20220930_htm.xml |
Filing Contents
This filing contains the following financial statements:
Balance Sheet
80 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Allowance for doubtful accounts |
AllowanceForDoubtfulAccountsReceivableCurrent
|
$77.00M | USD | Point-in-time |
| Allowance for doubtful accounts |
AllowanceForDoubtfulAccountsReceivableCurrent
|
$62.00M | USD | Point-in-time |
| Inventories classified in Other assets |
InventoryNoncurrent
|
$2.64B | USD | Point-in-time |
| Inventories classified in Other assets |
InventoryNoncurrent
|
$2.19B | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$11.14B | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$8.10B | USD | Point-in-time |
| Accumulated depreciation |
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
$18.19B | USD | Point-in-time |
| Accumulated depreciation |
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
$17.92B | USD | Point-in-time |
| Common stock, par value (in dollars per share) |
CommonStockParOrStatedValuePerShare
|
$0.50 | USD | Point-in-time |
| Common stock, par value (in dollars per share) |
CommonStockParOrStatedValuePerShare
|
$0.50 | USD | Point-in-time |
| Short-term investments |
ShortTermInvestments
|
$103.00M | USD | Point-in-time |
| Short-term investments |
ShortTermInvestments
|
- | USD | Point-in-time |
| Common stock, authorized (shares) |
CommonStockSharesAuthorized
|
6.50B | shares | Point-in-time |
| Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021) |
AccountsReceivableNetCurrent
|
$9.23B | USD | Point-in-time |
| Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021) |
AccountsReceivableNetCurrent
|
$9.48B | USD | Point-in-time |
| Common stock, authorized (shares) |
CommonStockSharesAuthorized
|
6.50B | shares | Point-in-time |
| Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note 7) |
InventoryNet
|
$5.61B | USD | Point-in-time |
| Common stock, issued (in shares) |
CommonStockSharesIssued
|
3.58B | shares | Point-in-time |
| Common stock, issued (in shares) |
CommonStockSharesIssued
|
3.58B | shares | Point-in-time |
| Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note 7) |
InventoryNet
|
$5.95B | USD | Point-in-time |
| Treasury stock (in shares) |
TreasuryStockCommonShares
|
1.04B | shares | Point-in-time |
| Other current assets |
DeferredIncomeTaxesAndOtherAssetsCurrent
|
$7.22B | USD | Point-in-time |
| Treasury stock (in shares) |
TreasuryStockCommonShares
|
1.05B | shares | Point-in-time |
| Other current assets |
DeferredIncomeTaxesAndOtherAssetsCurrent
|
$6.99B | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$33.56B | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$30.27B | USD | Point-in-time |
| Investments |
MarketableSecuritiesNoncurrent
|
$370.00M | USD | Point-in-time |
| Investments |
MarketableSecuritiesNoncurrent
|
$984.00M | USD | Point-in-time |
| Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021 |
PropertyPlantAndEquipmentNet
|
$19.28B | USD | Point-in-time |
| Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021 |
PropertyPlantAndEquipmentNet
|
$20.42B | USD | Point-in-time |
| Goodwill |
Goodwill
|
$21.16B | USD | Point-in-time |
| Goodwill |
Goodwill
|
$21.26B | USD | Point-in-time |
| Other Intangibles, Net |
IntangibleAssetsNetExcludingGoodwill
|
$21.37B | USD | Point-in-time |
| Other Intangibles, Net |
IntangibleAssetsNetExcludingGoodwill
|
$22.93B | USD | Point-in-time |
| Other Assets |
DeferredIncomeTaxesAndOtherAssetsNoncurrent
|
$9.58B | USD | Point-in-time |
| Other Assets |
DeferredIncomeTaxesAndOtherAssetsNoncurrent
|
$11.58B | USD | Point-in-time |
| Total Assets |
Assets
|
$107.08B | USD | Point-in-time |
| Total Assets |
Assets
|
$105.69B | USD | Point-in-time |
| Loans payable and current portion of long-term debt |
DebtCurrent
|
$1.94B | USD | Point-in-time |
| Loans payable and current portion of long-term debt |
DebtCurrent
|
$2.41B | USD | Point-in-time |
| Trade accounts payable |
AccountsPayableCurrent
|
$3.37B | USD | Point-in-time |
| Trade accounts payable |
AccountsPayableCurrent
|
$4.61B | USD | Point-in-time |
| Accrued and other current liabilities |
OtherLiabilitiesCurrent
|
$13.86B | USD | Point-in-time |
| Accrued and other current liabilities |
OtherLiabilitiesCurrent
|
$14.22B | USD | Point-in-time |
| Income taxes payable |
AccruedIncomeTaxesCurrent
|
$1.22B | USD | Point-in-time |
| Income taxes payable |
AccruedIncomeTaxesCurrent
|
$1.70B | USD | Point-in-time |
| Dividends payable |
DividendsPayableCurrent
|
$1.77B | USD | Point-in-time |
| Dividends payable |
DividendsPayableCurrent
|
$1.77B | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$23.00B | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$23.87B | USD | Point-in-time |
| Long-Term Debt |
LongTermDebtNoncurrent
|
$28.48B | USD | Point-in-time |
| Long-Term Debt |
LongTermDebtNoncurrent
|
$30.69B | USD | Point-in-time |
| Deferred Income Taxes |
DeferredIncomeTaxLiabilitiesNet
|
$3.44B | USD | Point-in-time |
| Deferred Income Taxes |
DeferredIncomeTaxLiabilitiesNet
|
$2.42B | USD | Point-in-time |
| Other Noncurrent Liabilities |
OtherLiabilitiesNoncurrent
|
$8.66B | USD | Point-in-time |
| Other Noncurrent Liabilities |
OtherLiabilitiesNoncurrent
|
$9.43B | USD | Point-in-time |
| Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021 |
CommonStockValue
|
$1.79B | USD | Point-in-time |
| Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021 |
CommonStockValue
|
$1.79B | USD | Point-in-time |
| Other paid-in capital |
AdditionalPaidInCapitalCommonStock
|
$44.24B | USD | Point-in-time |
| Other paid-in capital |
AdditionalPaidInCapitalCommonStock
|
$44.24B | USD | Point-in-time |
| Retained earnings |
RetainedEarningsAccumulatedDeficit
|
$53.70B | USD | Point-in-time |
| Retained earnings |
RetainedEarningsAccumulatedDeficit
|
$59.93B | USD | Point-in-time |
| Accumulated other comprehensive loss |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$-4.43B | USD | Point-in-time |
| Accumulated other comprehensive loss |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$-4.74B | USD | Point-in-time |
| Stockholders' equity before deduction for treasury stock |
StockholdersEquityBeforeTreasuryStock
|
$101.22B | USD | Point-in-time |
| Stockholders' equity before deduction for treasury stock |
StockholdersEquityBeforeTreasuryStock
|
$95.29B | USD | Point-in-time |
| Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021 |
TreasuryStockCommonValue
|
$56.76B | USD | Point-in-time |
| Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021 |
TreasuryStockCommonValue
|
$57.11B | USD | Point-in-time |
| Total Merck & Co., Inc. stockholders equity |
StockholdersEquity
|
$44.46B | USD | Point-in-time |
| Total Merck & Co., Inc. stockholders equity |
StockholdersEquity
|
$38.18B | USD | Point-in-time |
| Noncontrolling Interests |
MinorityInterest
|
$73.00M | USD | Point-in-time |
| Noncontrolling Interests |
MinorityInterest
|
$66.00M | USD | Point-in-time |
| Total equity |
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
$35.86B | USD | Point-in-time |
| Total equity |
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
$43.32B | USD | Point-in-time |
| Total equity |
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
$38.26B | USD | Point-in-time |
| Total equity |
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
$44.52B | USD | Point-in-time |
| Total equity |
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
$25.40B | USD | Point-in-time |
| Total equity |
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
$33.39B | USD | Point-in-time |
| Liabilities and Equity |
LiabilitiesAndStockholdersEquity
|
$107.08B | USD | Point-in-time |
| Liabilities and Equity |
LiabilitiesAndStockholdersEquity
|
$105.69B | USD | Point-in-time |
Income Statement
80 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Sales |
Revenues
|
$14.96B | USD | 1 Quarter |
| Sales |
Revenues
|
$45.45B | USD | 3 Qtrs |
| Sales |
Revenues
|
$13.15B | USD | 1 Quarter |
| Sales |
Revenues
|
$35.18B | USD | 3 Qtrs |
| Cost of sales |
CostOfGoodsAndServicesSold
|
$9.75B | USD | 3 Qtrs |
| Cost of sales |
CostOfGoodsAndServicesSold
|
$13.53B | USD | 3 Qtrs |
| Cost of sales |
CostOfGoodsAndServicesSold
|
$3.45B | USD | 1 Quarter |
| Cost of sales |
CostOfGoodsAndServicesSold
|
$3.93B | USD | 1 Quarter |
| Selling, general and administrative |
SellingGeneralAndAdministrativeExpense
|
$2.34B | USD | 1 Quarter |
| Selling, general and administrative |
SellingGeneralAndAdministrativeExpense
|
$2.52B | USD | 1 Quarter |
| Selling, general and administrative |
SellingGeneralAndAdministrativeExpense
|
$6.80B | USD | 3 Qtrs |
| Selling, general and administrative |
SellingGeneralAndAdministrativeExpense
|
$7.36B | USD | 3 Qtrs |
| Research and development |
ResearchAndDevelopmentExpense
|
$4.40B | USD | 1 Quarter |
| Research and development |
ResearchAndDevelopmentExpense
|
$9.18B | USD | 3 Qtrs |
| Research and development |
ResearchAndDevelopmentExpense
|
$9.77B | USD | 3 Qtrs |
| Research and development |
ResearchAndDevelopmentExpense
|
$2.44B | USD | 1 Quarter |
| Restructuring costs |
RestructuringCharges
|
$107.00M | USD | 1 Quarter |
| Restructuring costs |
RestructuringCharges
|
$487.00M | USD | 3 Qtrs |
| Restructuring costs |
RestructuringCharges
|
$94.00M | USD | 1 Quarter |
| Restructuring costs |
RestructuringCharges
|
$288.00M | USD | 3 Qtrs |
| Other (income) expense, net |
OtherNonoperatingIncomeExpense
|
$-429.00M | USD | 1 Quarter |
| Other (income) expense, net |
OtherNonoperatingIncomeExpense
|
$-1.58B | USD | 3 Qtrs |
| Other (income) expense, net |
OtherNonoperatingIncomeExpense
|
$450.00M | USD | 1 Quarter |
| Other (income) expense, net |
OtherNonoperatingIncomeExpense
|
$1.01B | USD | 3 Qtrs |
| Total Costs, Expenses and Other |
CostsExpensesAndOther
|
$32.52B | USD | 3 Qtrs |
| Total Costs, Expenses and Other |
CostsExpensesAndOther
|
$11.38B | USD | 1 Quarter |
| Total Costs, Expenses and Other |
CostsExpensesAndOther
|
$25.21B | USD | 3 Qtrs |
| Total Costs, Expenses and Other |
CostsExpensesAndOther
|
$7.89B | USD | 1 Quarter |
| Income from Continuing Operations Before Taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
$12.93B | USD | 3 Qtrs |
| Income from Continuing Operations Before Taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
$5.27B | USD | 1 Quarter |
| Income from Continuing Operations Before Taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
$3.58B | USD | 1 Quarter |
| Income from Continuing Operations Before Taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
$9.97B | USD | 3 Qtrs |
| Taxes on Income from Continuing Operations |
IncomeTaxExpenseBenefit
|
$1.44B | USD | 3 Qtrs |
| Taxes on Income from Continuing Operations |
IncomeTaxExpenseBenefit
|
$1.42B | USD | 3 Qtrs |
| Taxes on Income from Continuing Operations |
IncomeTaxExpenseBenefit
|
$330.00M | USD | 1 Quarter |
| Taxes on Income from Continuing Operations |
IncomeTaxExpenseBenefit
|
$695.00M | USD | 1 Quarter |
| Net Income from Continuing Operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$11.51B | USD | 3 Qtrs |
| Net Income from Continuing Operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$8.53B | USD | 3 Qtrs |
| Net Income from Continuing Operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$4.57B | USD | 1 Quarter |
| Net Income from Continuing Operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$3.25B | USD | 1 Quarter |
| Less: Net Income Attributable to Noncontrolling Interests |
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
|
$5.00M | USD | 1 Quarter |
| Less: Net Income Attributable to Noncontrolling Interests |
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
|
$9.00M | USD | 3 Qtrs |
| Less: Net Income Attributable to Noncontrolling Interests |
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
|
$6.00M | USD | 3 Qtrs |
| Less: Net Income Attributable to Noncontrolling Interests |
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
|
$4.00M | USD | 1 Quarter |
| Net Income from Continuing Operations Attributable to Merck & Co., Inc. |
IncomeLossFromContinuingOperations
|
$8.53B | USD | 3 Qtrs |
| Net Income from Continuing Operations Attributable to Merck & Co., Inc. |
IncomeLossFromContinuingOperations
|
$11.50B | USD | 3 Qtrs |
| Net Income from Continuing Operations Attributable to Merck & Co., Inc. |
IncomeLossFromContinuingOperations
|
$4.57B | USD | 1 Quarter |
| Net Income from Continuing Operations Attributable to Merck & Co., Inc. |
IncomeLossFromContinuingOperations
|
$3.25B | USD | 1 Quarter |
| Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests |
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
- | USD | 3 Qtrs |
| Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests |
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
$766.00M | USD | 3 Qtrs |
| Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests |
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
- | USD | 1 Quarter |
| Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests |
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
- | USD | 1 Quarter |
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$3.25B | USD | 1 Quarter |
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$9.29B | USD | 3 Qtrs |
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$4.57B | USD | 1 Quarter |
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$11.50B | USD | 3 Qtrs |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerBasicShare
|
$3.37 | USD | 3 Qtrs |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerBasicShare
|
$1.81 | USD | 1 Quarter |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerBasicShare
|
$4.55 | USD | 3 Qtrs |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerBasicShare
|
$1.28 | USD | 1 Quarter |
| Income from Discontinued Operations (in dollars per share) |
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
|
- | USD | 1 Quarter |
| Income from Discontinued Operations (in dollars per share) |
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
|
$0.30 | USD | 3 Qtrs |
| Income from Discontinued Operations (in dollars per share) |
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
|
- | USD | 1 Quarter |
| Income from Discontinued Operations (in dollars per share) |
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
|
- | USD | 3 Qtrs |
| Net Income (in dollars per share) |
EarningsPerShareBasic
|
$1.81 | USD | 1 Quarter |
| Net Income (in dollars per share) |
EarningsPerShareBasic
|
$3.67 | USD | 3 Qtrs |
| Net Income (in dollars per share) |
EarningsPerShareBasic
|
$1.28 | USD | 1 Quarter |
| Net Income (in dollars per share) |
EarningsPerShareBasic
|
$4.55 | USD | 3 Qtrs |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerDilutedShare
|
$3.36 | USD | 3 Qtrs |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerDilutedShare
|
$1.28 | USD | 1 Quarter |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerDilutedShare
|
$1.80 | USD | 1 Quarter |
| Income from Continuing Operations (in dollars per share) |
IncomeLossFromContinuingOperationsPerDilutedShare
|
$4.53 | USD | 3 Qtrs |
| Income from Discontinued Operations (in dollars per share) |
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
- | USD | 3 Qtrs |
| Income from Discontinued Operations (in dollars per share) |
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
- | USD | 1 Quarter |
| Income from Discontinued Operations (in dollars per share) |
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
$0.30 | USD | 3 Qtrs |
| Income from Discontinued Operations (in dollars per share) |
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
- | USD | 1 Quarter |
| Net Income (in dollars per share) |
EarningsPerShareDiluted
|
$3.66 | USD | 3 Qtrs |
| Net Income (in dollars per share) |
EarningsPerShareDiluted
|
$1.80 | USD | 1 Quarter |
| Net Income (in dollars per share) |
EarningsPerShareDiluted
|
$4.53 | USD | 3 Qtrs |
| Net Income (in dollars per share) |
EarningsPerShareDiluted
|
$1.28 | USD | 1 Quarter |
Cash Flow Statement
80 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Restricted cash |
RestrictedCashAndCashEquivalents
|
$103.00M | USD | Point-in-time |
| Restricted cash |
RestrictedCashAndCashEquivalents
|
$134.00M | USD | Point-in-time |
| Restricted cash |
RestrictedCashAndCashEquivalents
|
$71.00M | USD | Point-in-time |
| Restricted cash |
RestrictedCashAndCashEquivalents
|
$30.00M | USD | Point-in-time |
| Net income from continuing operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$11.51B | USD | 3 Qtrs |
| Net income from continuing operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$8.53B | USD | 3 Qtrs |
| Net income from continuing operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$4.57B | USD | 1 Quarter |
| Net income from continuing operations |
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
$3.25B | USD | 1 Quarter |
| Amortization |
AdjustmentForAmortization
|
$1.62B | USD | 3 Qtrs |
| Amortization |
AdjustmentForAmortization
|
$1.23B | USD | 3 Qtrs |
| Depreciation |
Depreciation
|
$1.39B | USD | 3 Qtrs |
| Depreciation |
Depreciation
|
$1.15B | USD | 3 Qtrs |
| Intangible asset impairment charges |
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
$910.00M | USD | 3 Qtrs |
| Intangible asset impairment charges |
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
- | USD | 3 Qtrs |
| Loss (income) from investments in equity securities, net |
EquitySecuritiesFvNiGainLoss
|
$-1.36B | USD | 3 Qtrs |
| Loss (income) from investments in equity securities, net |
EquitySecuritiesFvNiGainLoss
|
$683.00M | USD | 1 Quarter |
| Loss (income) from investments in equity securities, net |
EquitySecuritiesFvNiGainLoss
|
$-371.00M | USD | 1 Quarter |
| Loss (income) from investments in equity securities, net |
EquitySecuritiesFvNiGainLoss
|
$1.53B | USD | 3 Qtrs |
| Charge for the acquisition of Pandion Therapeutics, Inc. |
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
$1.56B | USD | 3 Qtrs |
| Charge for the acquisition of Pandion Therapeutics, Inc. |
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
- | USD | 3 Qtrs |
| Deferred income taxes |
DeferredIncomeTaxExpenseBenefit
|
$-1.26B | USD | 3 Qtrs |
| Deferred income taxes |
DeferredIncomeTaxExpenseBenefit
|
$28.00M | USD | 3 Qtrs |
| Share-based compensation |
ShareBasedCompensation
|
$360.00M | USD | 3 Qtrs |
| Share-based compensation |
ShareBasedCompensation
|
$396.00M | USD | 3 Qtrs |
| Other |
OtherNoncashIncomeExpense
|
$-1.17B | USD | 3 Qtrs |
| Other |
OtherNoncashIncomeExpense
|
$-499.00M | USD | 3 Qtrs |
| Net changes in assets and liabilities |
IncreaseDecreaseInOperatingCapital
|
$2.44B | USD | 3 Qtrs |
| Net changes in assets and liabilities |
IncreaseDecreaseInOperatingCapital
|
$3.79B | USD | 3 Qtrs |
| Net Cash Provided by Operating Activities of Continuing Operations |
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
$14.66B | USD | 3 Qtrs |
| Net Cash Provided by Operating Activities of Continuing Operations |
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
$8.03B | USD | 3 Qtrs |
| Capital expenditures |
PaymentsToAcquireProductiveAssets
|
$3.24B | USD | 3 Qtrs |
| Capital expenditures |
PaymentsToAcquireProductiveAssets
|
$3.24B | USD | 3 Qtrs |
| Purchases of securities and other investments |
PaymentsToAcquireMarketableSecurities
|
$710.00M | USD | 3 Qtrs |
| Purchases of securities and other investments |
PaymentsToAcquireMarketableSecurities
|
$1.00M | USD | 3 Qtrs |
| Proceeds from sales of securities and other investments |
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
$497.00M | USD | 3 Qtrs |
| Proceeds from sales of securities and other investments |
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
$709.00M | USD | 3 Qtrs |
| Acquisition of Pandion Therapeutics, Inc., net of cash acquired |
PaymentsToAcquireBusinessTwoNetOfCashAcquired
|
- | USD | 3 Qtrs |
| Acquisition of Pandion Therapeutics, Inc., net of cash acquired |
PaymentsToAcquireBusinessTwoNetOfCashAcquired
|
$1.55B | USD | 3 Qtrs |
| Other acquisitions, net of cash acquired |
PaymentsToAcquireBusinessesNetOfCashAcquired
|
$89.00M | USD | 3 Qtrs |
| Other acquisitions, net of cash acquired |
PaymentsToAcquireBusinessesNetOfCashAcquired
|
$121.00M | USD | 3 Qtrs |
| Other |
PaymentsForProceedsFromOtherInvestingActivities
|
$-15.00M | USD | 3 Qtrs |
| Other |
PaymentsForProceedsFromOtherInvestingActivities
|
$-149.00M | USD | 3 Qtrs |
| Net Cash Used in Investing Activities of Continuing Operations |
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
$-3.21B | USD | 3 Qtrs |
| Net Cash Used in Investing Activities of Continuing Operations |
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
$-4.37B | USD | 3 Qtrs |
| Net change in short-term borrowings |
ProceedsFromRepaymentsOfShortTermDebt
|
- | USD | 3 Qtrs |
| Net change in short-term borrowings |
ProceedsFromRepaymentsOfShortTermDebt
|
$-3.98B | USD | 3 Qtrs |
| Payments on debt |
RepaymentsOfLongTermDebt
|
$2.25B | USD | 3 Qtrs |
| Payments on debt |
RepaymentsOfLongTermDebt
|
$1.15B | USD | 3 Qtrs |
| Distribution from Organon & Co. |
DisposalGroupInclDiscontinuedOperationsDistributionReceived
|
- | USD | 3 Qtrs |
| Distribution from Organon & Co. |
DisposalGroupInclDiscontinuedOperationsDistributionReceived
|
$9.00B | USD | 3 Qtrs |
| Purchases of treasury stock |
PaymentsForRepurchaseOfCommonStock
|
- | USD | 3 Qtrs |
| Purchases of treasury stock |
PaymentsForRepurchaseOfCommonStock
|
$822.00M | USD | 3 Qtrs |
| Dividends paid to stockholders |
PaymentsOfDividendsCommonStock
|
$4.97B | USD | 3 Qtrs |
| Dividends paid to stockholders |
PaymentsOfDividendsCommonStock
|
$5.26B | USD | 3 Qtrs |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$119.00M | USD | 3 Qtrs |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$68.00M | USD | 3 Qtrs |
| Other |
ProceedsFromPaymentsForOtherFinancingActivities
|
$-172.00M | USD | 3 Qtrs |
| Other |
ProceedsFromPaymentsForOtherFinancingActivities
|
$-253.00M | USD | 3 Qtrs |
| Net Cash Used in Financing Activities of Continuing Operations |
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
$-7.57B | USD | 3 Qtrs |
| Net Cash Used in Financing Activities of Continuing Operations |
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
$-2.11B | USD | 3 Qtrs |
| Net cash provided by operating activities |
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
|
- | USD | 3 Qtrs |
| Net cash provided by operating activities |
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
|
$1.05B | USD | 3 Qtrs |
| Net cash used in investing activities |
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
|
- | USD | 3 Qtrs |
| Net cash used in investing activities |
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
|
$-134.00M | USD | 3 Qtrs |
| Net cash used in financing activities |
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
|
$-504.00M | USD | 3 Qtrs |
| Net cash used in financing activities |
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
|
- | USD | 3 Qtrs |
| Net Cash Flows Provided by Discontinued Operations |
NetCashProvidedByUsedInDiscontinuedOperations
|
$413.00M | USD | 3 Qtrs |
| Net Cash Flows Provided by Discontinued Operations |
NetCashProvidedByUsedInDiscontinuedOperations
|
- | USD | 3 Qtrs |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash |
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$-776.00M | USD | 3 Qtrs |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash |
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$-65.00M | USD | 3 Qtrs |
| Net Increase in Cash, Cash Equivalents and Restricted Cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$3.11B | USD | 3 Qtrs |
| Net Increase in Cash, Cash Equivalents and Restricted Cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$1.89B | USD | 3 Qtrs |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$10.05B | USD | Point-in-time |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$11.28B | USD | Point-in-time |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$8.17B | USD | Point-in-time |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$8.15B | USD | Point-in-time |
| Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September 30, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$10.05B | USD | Point-in-time |
| Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September 30, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$11.28B | USD | Point-in-time |
| Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September 30, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$8.17B | USD | Point-in-time |
| Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September 30, 2022 and 2021, respectively, included in Other current assets) |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$8.15B | USD | Point-in-time |
Comprehensive Income
24 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$3.25B | USD | 1 Quarter |
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$9.29B | USD | 3 Qtrs |
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$4.57B | USD | 1 Quarter |
| Net Income Attributable to Merck & Co., Inc. |
NetIncomeLoss
|
$11.50B | USD | 3 Qtrs |
| Net unrealized gain on derivatives, net of reclassifications |
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
|
$84.00M | USD | 1 Quarter |
| Net unrealized gain on derivatives, net of reclassifications |
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
|
$584.00M | USD | 3 Qtrs |
| Net unrealized gain on derivatives, net of reclassifications |
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
|
$338.00M | USD | 1 Quarter |
| Net unrealized gain on derivatives, net of reclassifications |
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
|
$324.00M | USD | 3 Qtrs |
| Benefit plan net (loss) gain and prior service (cost) credit, net of amortization |
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
|
$-1.52B | USD | 3 Qtrs |
| Benefit plan net (loss) gain and prior service (cost) credit, net of amortization |
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
|
$-92.00M | USD | 3 Qtrs |
| Benefit plan net (loss) gain and prior service (cost) credit, net of amortization |
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
|
$-38.00M | USD | 1 Quarter |
| Benefit plan net (loss) gain and prior service (cost) credit, net of amortization |
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
|
$186.00M | USD | 1 Quarter |
| Cumulative translation adjustment |
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
$-84.00M | USD | 1 Quarter |
| Cumulative translation adjustment |
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
$-568.00M | USD | 1 Quarter |
| Cumulative translation adjustment |
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
$-251.00M | USD | 3 Qtrs |
| Cumulative translation adjustment |
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
$-990.00M | USD | 3 Qtrs |
| Other comprehensive income (loss), net of taxes |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
$1.59B | USD | 3 Qtrs |
| Other comprehensive income (loss), net of taxes |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
$-314.00M | USD | 3 Qtrs |
| Other comprehensive income (loss), net of taxes |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
$38.00M | USD | 1 Quarter |
| Other comprehensive income (loss), net of taxes |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
$-416.00M | USD | 1 Quarter |
| Comprehensive Income Attributable to Merck & Co., Inc. |
ComprehensiveIncomeNetOfTax
|
$10.89B | USD | 3 Qtrs |
| Comprehensive Income Attributable to Merck & Co., Inc. |
ComprehensiveIncomeNetOfTax
|
$2.83B | USD | 1 Quarter |
| Comprehensive Income Attributable to Merck & Co., Inc. |
ComprehensiveIncomeNetOfTax
|
$4.61B | USD | 1 Quarter |
| Comprehensive Income Attributable to Merck & Co., Inc. |
ComprehensiveIncomeNetOfTax
|
$11.19B | USD | 3 Qtrs |
Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.